Agenus Inc at Jefferies Virtual London Healthcare Conference Transcript
Hello, everyone. Welcome to the Virtual Jefferies London Healthcare Conference. My name is Jeet Mukherjee. I'm one of the Biotech Equity Research Associates here at Jefferies. And it's my pleasure to have Agenus here with us for this session. And speaking on their behalf is their President and COO, Jennifer Buell. So Jennifer, pleasure to have you with us.
Jeet, thank you very much. We're thrilled to be here. Glad to connect. I'm glad to be part of the conference.
Questions & Answers
Not a problem. So Jennifer, to start things off, at a high level, I think it goes without saying that Agenus has quite a robust R&D pipeline, spanning from PD-1, CTLA-4, TIGIT, just to name a few. As a company, how are you guys prioritizing these assets going forward as they continue to advance in the clinic as well as other assets
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
